Evaluating photodynamic therapy versus brolucizumab as a second-line treatment for polypoidal choroidal vasculopathy

Evaluating photodynamic therapy versus brolucizumab as a second-line treatment for polypoidal choroidal vasculopathy

Abstract Background To compare the one-year outcomes between intravitreal brolucizumab (IVBr) monotherapy and photodynamic therapy (PDT) as a second-line treatment in patients with polypoidal choroidal vasculopathy (PCV) who did not respond to first-line therapy. Methods This case–control study incl...

Full description

Bibliographic Details
Main Authors: Ryoh Funatsu, Hiroto Terasaki, Naohisa Mihara, Shozo Sonoda, Hideki Shiihara, Taiji Sakamoto
Format: Article
Language:English
Published: BMC 2024-04-01
Series:International Journal of Retina and Vitreous
Subjects:
Polypoidal choroidal vasculopathy
Photodynamic therapy
Brolucizumab
Neovascular age-related macular degeneration
Online Access:https://doi.org/10.1186/s40942-024-00553-5

Similar Items

Similar Items